1. Home
  2. ZVIA vs VTVT Comparison

ZVIA vs VTVT Comparison

Compare ZVIA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

HOLD

Current Price

$1.36

Market Cap

126.3M

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$29.63

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVIA
VTVT
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.3M
148.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
ZVIA
VTVT
Price
$1.36
$29.63
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$4.93
$53.00
AVG Volume (30 Days)
385.3K
103.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
55.88
N/A
EPS
N/A
N/A
Revenue
$161,259,000.00
N/A
Revenue This Year
$8.30
N/A
Revenue Next Year
$6.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.01
N/A
52 Week Low
$1.11
$14.55
52 Week High
$3.22
$44.00

Technical Indicators

Market Signals
Indicator
ZVIA
VTVT
Relative Strength Index (RSI) 35.98 36.48
Support Level $1.27 $22.92
Resistance Level $1.53 $33.76
Average True Range (ATR) 0.11 2.07
MACD -0.04 -0.22
Stochastic Oscillator 10.65 2.96

Price Performance

Historical Comparison
ZVIA
VTVT

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: